Wednesday, February 10, 2010, 12:14am EST - Canadian Markets open in 9 hours and 16 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Valeant Pharmaceuticals International (VRX)

 On Feb 9: 35.55 USD  Up 1.06 (3.07%)  
MORE ON VRX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
VALEANT PHARMA INTL (NYSE:VRX) Delayed quote dataEdit
After Hours: 35.55 0.00 (0.00%) as of 4:31pm EST on 02/09/10
Last Trade: 35.55 USD
Trade Time: Feb 9
Change: Up 1.06 (3.07%)
Prev Close: 34.49
Open: 34.76
Bid: N/A
Ask: N/A
1y Target Est: 17.00
Day's Range: 34.56 - 35.69
52wk Range: 15.64 - 35.80
Volume: 811,879
Avg Vol (3m): 677,422
Market Cap: 2.89B
P/E (ttm): N/A
EPS (ttm): -0.09
Div & Yield: N/A (N/A%)
Valeant Pharmaceuticals International (VRX)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add VRX to Portfolio   Download Data

HEADLINES
• Valeant Pharmaceuticals to Announce 2009 Fourth Quarter and Year Results on February 22, 2010
PRNewswire (Mon, Feb 8)
• Coverage initiated on Valeant Pharmaceuticals by Jefferies & Co
Briefing.com (Fri, Feb 5)
• 3 Stocks Ready to Roar
at Motley Fool (Tue, Jan 19)
• VALEANT PHARMACEUTICALS INTERNATIONAL Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Mon, Jan 11)
• Valeant Pharmaceuticals to Hold Conference Call to Announce 2010 Financial Guidance scheduled for 9:00 am ET today
CCBN (Fri, Jan 8)
• Valeant Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
PRNewswire (Wed, Jan 6)
• Valeant Pharmaceuticals to Hold Conference Call to Announce 2010 Financial Guidance
PRNewswire (Tue, Jan 5)
• Valeant Drug Accepted by FDA
Zacks.com (Mon, Jan 4)
• Aetna, Nvidia, MGM Mirage, Compugen are movers
AP (Wed, Dec 30)
• Valeant: Regulators review retigabine applications
AP (Wed, Dec 30)
• FDA Accepts NDA Filing for Retigabine
PRNewswire (Wed, Dec 30)
More Headlines for VRX...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.5
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products principally in the therapeutic areas of neurology, dermatology, and infectious ...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices